WO2008157688A3 - Synthesis and use of anti-reverse phosphorothioate analogs of the messenger rna cap - Google Patents
Synthesis and use of anti-reverse phosphorothioate analogs of the messenger rna cap Download PDFInfo
- Publication number
- WO2008157688A3 WO2008157688A3 PCT/US2008/067494 US2008067494W WO2008157688A3 WO 2008157688 A3 WO2008157688 A3 WO 2008157688A3 US 2008067494 W US2008067494 W US 2008067494W WO 2008157688 A3 WO2008157688 A3 WO 2008157688A3
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- analogs
- arcas
- cap
- reverse
- synthesis
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
- C07H21/00—Compounds containing two or more mononucleotide units having separate phosphate or polyphosphate groups linked by saccharide radicals of nucleoside groups, e.g. nucleic acids
- C07H21/02—Compounds containing two or more mononucleotide units having separate phosphate or polyphosphate groups linked by saccharide radicals of nucleoside groups, e.g. nucleic acids with ribosyl as saccharide radical
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
- C07H19/00—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof
- C07H19/02—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof sharing nitrogen
- C07H19/04—Heterocyclic radicals containing only nitrogen atoms as ring hetero atom
- C07H19/16—Purine radicals
- C07H19/20—Purine radicals with the saccharide radical esterified by phosphoric or polyphosphoric acids
- C07H19/207—Purine radicals with the saccharide radical esterified by phosphoric or polyphosphoric acids the phosphoric or polyphosphoric acids being esterified by a further hydroxylic compound, e.g. flavine adenine dinucleotide or nicotinamide-adenine dinucleotide
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
- C07H1/00—Processes for the preparation of sugar derivatives
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K1/00—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12P—FERMENTATION OR ENZYME-USING PROCESSES TO SYNTHESISE A DESIRED CHEMICAL COMPOUND OR COMPOSITION OR TO SEPARATE OPTICAL ISOMERS FROM A RACEMIC MIXTURE
- C12P19/00—Preparation of compounds containing saccharide radicals
- C12P19/26—Preparation of nitrogen-containing carbohydrates
- C12P19/28—N-glycosides
- C12P19/30—Nucleotides
- C12P19/34—Polynucleotides, e.g. nucleic acids, oligoribonucleotides
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12P—FERMENTATION OR ENZYME-USING PROCESSES TO SYNTHESISE A DESIRED CHEMICAL COMPOUND OR COMPOSITION OR TO SEPARATE OPTICAL ISOMERS FROM A RACEMIC MIXTURE
- C12P21/00—Preparation of peptides or proteins
- C12P21/02—Preparation of peptides or proteins having a known sequence of two or more amino acids, e.g. glutathione
Abstract
Priority Applications (11)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CA2692906A CA2692906C (en) | 2007-06-19 | 2008-06-19 | Synthesis and use of anti-reverse phosphorothioate analogs of the messenger rna cap |
DK08771474.7T DK2167523T3 (en) | 2007-06-19 | 2008-06-19 | SYNTHESIS AND USE OF ANTI-REVERSE PHOSPHOROTHIOAT ANALOGS OF THE MESSENGER RNA CAPPEN |
PL08771474T PL2167523T3 (en) | 2007-06-19 | 2008-06-19 | Synthesis and use of anti-reverse phosphorothioate analogs of the messenger rna cap |
SI200831256T SI2167523T1 (en) | 2007-06-19 | 2008-06-19 | Synthesis and use of anti-reverse phosphorothioate analogs of the messenger rna cap |
ES08771474.7T ES2500515T3 (en) | 2007-06-19 | 2008-06-19 | Synthesis and use of anti-reverse phosphorothioate analogues of the messenger RNA cap |
US12/280,282 US8153773B2 (en) | 2007-06-19 | 2008-06-19 | Synthesis and use of anti-reverse phosphorothioate analogs of the messenger RNA cap |
EA201070030A EA017740B1 (en) | 2007-06-19 | 2008-06-19 | Synthesis and use of anti-reverse phosphorothioate analogs of the messenger rna cap |
CN200880102959.9A CN101855231B (en) | 2007-06-19 | 2008-06-19 | Synthesis and use of anti-reverse phosphorothioate analogs of the messenger RNA cap |
EP08771474.7A EP2167523B1 (en) | 2007-06-19 | 2008-06-19 | Synthesis and use of anti-reverse phosphorothioate analogs of the messenger rna cap |
AU2008265683A AU2008265683B2 (en) | 2007-06-19 | 2008-06-19 | Synthesis and use of anti-reverse phosphorothioate analogs of the messenger RNA cap |
HRP20140771AT HRP20140771T1 (en) | 2007-06-19 | 2014-08-18 | Synthesis and use of anti-reverse phosphorothioate analogs of the messenger rna cap |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US94484207P | 2007-06-19 | 2007-06-19 | |
US60/944,842 | 2007-06-19 |
Publications (2)
Publication Number | Publication Date |
---|---|
WO2008157688A2 WO2008157688A2 (en) | 2008-12-24 |
WO2008157688A3 true WO2008157688A3 (en) | 2009-02-26 |
Family
ID=40156965
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/US2008/067494 WO2008157688A2 (en) | 2007-06-19 | 2008-06-19 | Synthesis and use of anti-reverse phosphorothioate analogs of the messenger rna cap |
Country Status (15)
Country | Link |
---|---|
US (1) | US8153773B2 (en) |
EP (1) | EP2167523B1 (en) |
CN (3) | CN104072561B (en) |
AU (1) | AU2008265683B2 (en) |
CA (1) | CA2692906C (en) |
CY (1) | CY1115525T1 (en) |
DK (1) | DK2167523T3 (en) |
EA (1) | EA017740B1 (en) |
ES (1) | ES2500515T3 (en) |
HK (1) | HK1200461A1 (en) |
HR (1) | HRP20140771T1 (en) |
PL (1) | PL2167523T3 (en) |
PT (1) | PT2167523E (en) |
SI (1) | SI2167523T1 (en) |
WO (1) | WO2008157688A2 (en) |
Cited By (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US8822663B2 (en) | 2010-08-06 | 2014-09-02 | Moderna Therapeutics, Inc. | Engineered nucleic acids and methods of use thereof |
US8999380B2 (en) | 2012-04-02 | 2015-04-07 | Moderna Therapeutics, Inc. | Modified polynucleotides for the production of biologics and proteins associated with human disease |
US9186372B2 (en) | 2011-12-16 | 2015-11-17 | Moderna Therapeutics, Inc. | Split dose administration |
US9220755B2 (en) | 2012-04-02 | 2015-12-29 | Moderna Therapeutics, Inc. | Modified polynucleotides for the production of proteins associated with blood and lymphatic disorders |
US9572897B2 (en) | 2012-04-02 | 2017-02-21 | Modernatx, Inc. | Modified polynucleotides for the production of cytoplasmic and cytoskeletal proteins |
US9587003B2 (en) | 2012-04-02 | 2017-03-07 | Modernatx, Inc. | Modified polynucleotides for the production of oncology-related proteins and peptides |
Families Citing this family (139)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CA2659301A1 (en) * | 2006-07-28 | 2008-02-07 | Applera Corporation | Dinucleotide mrna cap analogs |
WO2009058911A2 (en) * | 2007-10-31 | 2009-05-07 | Applied Biosystems Inc. | Preparation and isolation of 5' capped mrna |
EP2281579A1 (en) * | 2009-08-05 | 2011-02-09 | BioNTech AG | Vaccine composition comprising 5'-Cap modified RNA |
CN101671669B (en) * | 2009-08-27 | 2012-05-02 | 浙江大学 | Hepatocellular carcinoma targeting gene expression element AE and applications thereof |
CA2813466A1 (en) | 2010-10-01 | 2012-04-05 | Moderna Therapeutics, Inc. | Modified nucleosides, nucleotides, and nucleic acids that disrupt major groove binding partner interactions |
CA2831613A1 (en) | 2011-03-31 | 2012-10-04 | Moderna Therapeutics, Inc. | Delivery and formulation of engineered nucleic acids |
US9464124B2 (en) | 2011-09-12 | 2016-10-11 | Moderna Therapeutics, Inc. | Engineered nucleic acids and methods of use thereof |
CN110511939A (en) | 2011-10-03 | 2019-11-29 | 现代泰克斯公司 | Nucleosides, nucleotide and nucleic acid of modification and application thereof |
WO2013130824A1 (en) | 2012-02-29 | 2013-09-06 | Sangamo Biosciences, Inc. | Methods and compositions for treating huntington's disease |
PT2922554T (en) | 2012-11-26 | 2022-06-28 | Modernatx Inc | Terminally modified rna |
WO2014130955A1 (en) | 2013-02-25 | 2014-08-28 | Sangamo Biosciences, Inc. | Methods and compositions for enhancing nuclease-mediated gene disruption |
US8980864B2 (en) | 2013-03-15 | 2015-03-17 | Moderna Therapeutics, Inc. | Compositions and methods of altering cholesterol levels |
WO2015048744A2 (en) | 2013-09-30 | 2015-04-02 | Moderna Therapeutics, Inc. | Polynucleotides encoding immune modulating polypeptides |
SG11201602503TA (en) | 2013-10-03 | 2016-04-28 | Moderna Therapeutics Inc | Polynucleotides encoding low density lipoprotein receptor |
RU2693891C1 (en) | 2013-11-11 | 2019-07-05 | Сангамо Байосайенсиз, Инк. | Methods and compositions for treating huntington's disease |
HUE044540T2 (en) | 2013-11-13 | 2019-10-28 | Childrens Medical Center | Nuclease-mediated regulation of gene expression |
CA2931637C (en) | 2013-12-09 | 2023-10-10 | Sangamo Biosciences, Inc. | Methods and compositions for treating hemophilia |
AU2014375404C1 (en) | 2013-12-30 | 2020-11-19 | CureVac Manufacturing GmbH | Methods for RNA analysis |
EP3540060A1 (en) | 2013-12-30 | 2019-09-18 | CureVac AG | Methods for rna analysis |
LT3102673T (en) | 2014-02-03 | 2020-08-25 | Sangamo Therapeutics, Inc. | Methods and compositions for treatment of a beta thalessemia |
EP3929279A1 (en) | 2014-03-18 | 2021-12-29 | Sangamo Therapeutics, Inc. | Methods and compositions for regulation of zinc finger protein expression |
WO2015164748A1 (en) | 2014-04-24 | 2015-10-29 | Sangamo Biosciences, Inc. | Engineered transcription activator like effector (tale) proteins |
MX2016014565A (en) | 2014-05-08 | 2017-05-23 | Sangamo Biosciences Inc | Methods and compositions for treating huntington's disease. |
WO2015175642A2 (en) | 2014-05-13 | 2015-11-19 | Sangamo Biosciences, Inc. | Methods and compositions for prevention or treatment of a disease |
WO2015188056A1 (en) | 2014-06-05 | 2015-12-10 | Sangamo Biosciences, Inc. | Methods and compositions for nuclease design |
PT3155129T (en) | 2014-06-10 | 2019-05-16 | Curevac Ag | Methods and means for enhancing rna production |
US9757420B2 (en) | 2014-07-25 | 2017-09-12 | Sangamo Therapeutics, Inc. | Gene editing for HIV gene therapy |
US9616090B2 (en) | 2014-07-30 | 2017-04-11 | Sangamo Biosciences, Inc. | Gene correction of SCID-related genes in hematopoietic stem and progenitor cells |
US10889834B2 (en) | 2014-12-15 | 2021-01-12 | Sangamo Therapeutics, Inc. | Methods and compositions for enhancing targeted transgene integration |
EP3274454B1 (en) | 2015-03-25 | 2021-08-25 | Editas Medicine, Inc. | Crispr/cas-related methods, compositions and components |
WO2016161446A1 (en) | 2015-04-03 | 2016-10-06 | Dana-Farber Cancer Institute, Inc. | Composition and methods of genome editing of b-cells |
RU2749113C2 (en) | 2015-04-22 | 2021-06-04 | Куревак Аг | Rna-containing composition for treatment of tumor diseases |
WO2016182959A1 (en) | 2015-05-11 | 2016-11-17 | Editas Medicine, Inc. | Optimized crispr/cas9 systems and methods for gene editing in stem cells |
CA2985615A1 (en) | 2015-05-11 | 2016-11-17 | Editas Medicine, Inc. | Crispr/cas-related methods and compositions for treating hiv infection and aids |
SG10202112057QA (en) | 2015-05-12 | 2021-12-30 | Sangamo Therapeutics Inc | Nuclease-mediated regulation of gene expression |
EP3744843A1 (en) | 2015-05-29 | 2020-12-02 | CureVac Real Estate GmbH | A method for producing and purifying rna, comprising at least one step of tangential flow filtration |
WO2016201047A1 (en) | 2015-06-09 | 2016-12-15 | Editas Medicine, Inc. | Crispr/cas-related methods and compositions for improving transplantation |
US9957501B2 (en) | 2015-06-18 | 2018-05-01 | Sangamo Therapeutics, Inc. | Nuclease-mediated regulation of gene expression |
EP3317424B1 (en) | 2015-07-01 | 2023-09-06 | CureVac Manufacturing GmbH | Method for analysis of an rna molecule |
CN116590285A (en) | 2015-09-21 | 2023-08-15 | 垂林克生物技术有限公司 | Compositions and methods for synthesizing 5' -capped RNA |
EA037993B1 (en) | 2015-09-23 | 2021-06-21 | Сангамо Терапьютикс, Инк. | Htt repressors and uses thereof |
WO2017066797A1 (en) | 2015-10-16 | 2017-04-20 | Modernatx, Inc. | Trinucleotide mrna cap analogs |
WO2017066781A1 (en) | 2015-10-16 | 2017-04-20 | Modernatx, Inc. | Mrna cap analogs with modified phosphate linkage |
CA3001351A1 (en) | 2015-10-21 | 2017-04-27 | Editas Medicine, Inc. | Crispr/cas-related methods and compositions for treating hepatitis b virus |
CN109312338B (en) | 2015-10-30 | 2022-09-27 | 爱迪塔斯医药公司 | CRISPR/CAS related methods and compositions for treating herpes simplex virus |
AU2016361350B2 (en) | 2015-11-23 | 2023-04-06 | Sangamo Therapeutics, Inc. | Methods and compositions for engineering immunity |
US11352631B2 (en) | 2015-12-18 | 2022-06-07 | Sangamo Therapeutics, Inc. | Targeted disruption of the T cell receptor |
AU2016374253B2 (en) | 2015-12-18 | 2021-10-21 | Sangamo Therapeutics, Inc. | Targeted disruption of the MHC cell receptor |
EP3394280A1 (en) | 2015-12-23 | 2018-10-31 | CureVac AG | Method of rna in vitro transcription using a buffer containing a dicarboxylic acid or tricarboxylic acid or a salt thereof |
PL415967A1 (en) * | 2016-01-29 | 2017-07-31 | Univ Warszawski | 5'-thiophosphate analogs of 5' mRNA (capu) end, method for obtaining them and applications |
US20190049414A1 (en) | 2016-02-15 | 2019-02-14 | Curevac Ag | Method for analyzing by-products of rna in vitro transcription |
WO2017149139A1 (en) | 2016-03-03 | 2017-09-08 | Curevac Ag | Rna analysis by total hydrolysis |
WO2017162266A1 (en) | 2016-03-21 | 2017-09-28 | Biontech Rna Pharmaceuticals Gmbh | Rna replicon for versatile and efficient gene expression |
WO2017162265A1 (en) | 2016-03-21 | 2017-09-28 | Biontech Rna Pharmaceuticals Gmbh | Trans-replicating rna |
MA44732B1 (en) | 2016-04-22 | 2021-11-30 | BioNTech SE | Single-stranded RNA production processes |
US20180126003A1 (en) * | 2016-05-04 | 2018-05-10 | Curevac Ag | New targets for rna therapeutics |
EP3452493A1 (en) | 2016-05-04 | 2019-03-13 | CureVac AG | Nucleic acid molecules and uses thereof |
EP3452086A1 (en) | 2016-05-04 | 2019-03-13 | CureVac AG | Influenza mrna vaccines |
SG11201809710RA (en) | 2016-05-06 | 2018-11-29 | Juno Therapeutics Inc | Genetically engineered cells and methods of making the same |
ES2938210T3 (en) | 2016-07-13 | 2023-04-05 | Vertex Pharma | Methods, compositions and kits to increase the efficiency of genome editing |
CN109715205A (en) | 2016-08-19 | 2019-05-03 | 库瑞瓦格股份公司 | RNA use for cancer treatment |
AU2017315406B2 (en) | 2016-08-24 | 2021-04-01 | Sangamo Therapeutics, Inc. | Regulation of gene expression using engineered nucleases |
AU2017315414B2 (en) | 2016-08-24 | 2024-02-15 | Sangamo Therapeutics, Inc. | Engineered target specific nucleases |
US11219695B2 (en) | 2016-10-20 | 2022-01-11 | Sangamo Therapeutics, Inc. | Methods and compositions for the treatment of Fabry disease |
SG11201903460QA (en) | 2016-10-26 | 2019-05-30 | Curevac Ag | Lipid nanoparticle mrna vaccines |
CA3041668A1 (en) | 2016-10-31 | 2018-05-03 | Sangamo Therapeutics, Inc. | Gene correction of scid-related genes in hematopoietic stem and progenitor cells |
US11504389B2 (en) | 2016-12-01 | 2022-11-22 | Sangamo Therapeutics, Inc. | Tau modulators and methods and compositions for delivery thereof |
US11141476B2 (en) | 2016-12-23 | 2021-10-12 | Curevac Ag | MERS coronavirus vaccine |
EP3558355A2 (en) | 2016-12-23 | 2019-10-30 | CureVac AG | Henipavirus vaccine |
CA3054031A1 (en) | 2017-02-22 | 2018-08-30 | Crispr Therapeutics Ag | Compositions and methods for gene editing |
CN116693411A (en) | 2017-04-28 | 2023-09-05 | 爱康泰生治疗公司 | Novel carbonyl lipid and lipid nanoparticle formulations for delivery of nucleic acids |
EP3619322A4 (en) | 2017-05-03 | 2021-06-30 | Sangamo Therapeutics, Inc. | Methods and compositions for modification of a cystic fibrosis transmembrane conductance regulator (cftr) gene |
US11512287B2 (en) | 2017-06-16 | 2022-11-29 | Sangamo Therapeutics, Inc. | Targeted disruption of T cell and/or HLA receptors |
SG11201911430PA (en) | 2017-07-04 | 2020-01-30 | Curevac Ag | Novel nucleic acid molecules |
EP3673069A1 (en) | 2017-08-22 | 2020-07-01 | CureVac AG | Bunyavirales vaccine |
US20200283497A1 (en) | 2017-09-13 | 2020-09-10 | Biontech Cell & Gene Therapies Gmbh | Rna replicon for expressing at cell receptor or an artificial t cell receptor |
EP3681901B1 (en) | 2017-09-13 | 2024-03-27 | BioNTech SE | Method of enhancing rna expression in a cell |
CA3075549A1 (en) | 2017-09-13 | 2019-03-21 | Biontech Rna Pharmaceuticals Gmbh | Rna replicon for reprogramming somatic cells |
SG11202003247RA (en) | 2017-11-08 | 2020-05-28 | Curevac Ag | Rna sequence adaptation |
WO2019094725A2 (en) | 2017-11-09 | 2019-05-16 | Sangamo Therapeutics, Inc. | Genetic modification of cytokine inducible sh2-containing protein (cish) gene |
EP3723796A1 (en) | 2017-12-13 | 2020-10-21 | CureVac AG | Flavivirus vaccine |
WO2019122371A1 (en) | 2017-12-21 | 2019-06-27 | Curevac Ag | Linear double stranded dna coupled to a single support or a tag and methods for producing said linear double stranded dna |
BR112020014315A2 (en) | 2018-01-17 | 2020-12-08 | Vertex Pharmaceuticals Incorporated | DNA-PK INHIBITORS |
KR20200110687A (en) | 2018-01-17 | 2020-09-24 | 버텍스 파마슈티칼스 인코포레이티드 | Quinoxalinone compounds, compositions, methods and kits for increasing genome editing efficiency |
US20210060028A1 (en) | 2018-01-17 | 2021-03-04 | Vertex Pharmaceuticals Incorporated | Dna-pk inhibitors |
WO2019175356A1 (en) * | 2018-03-15 | 2019-09-19 | Biontech Rna Pharmaceuticals Gmbh | 5'-cap-trinucleotide- or higher oligonucleotide compounds and their uses in stabilizing rna, expressing proteins and in therapy |
US20210361761A1 (en) | 2018-04-05 | 2021-11-25 | Curevac Ag | Novel yellow fever nucleic acid molecules for vaccination |
EP3781591A1 (en) | 2018-04-17 | 2021-02-24 | CureVac AG | Novel rsv rna molecules and compositions for vaccination |
US11690921B2 (en) | 2018-05-18 | 2023-07-04 | Sangamo Therapeutics, Inc. | Delivery of target specific nucleases |
EP3813874A1 (en) | 2018-06-27 | 2021-05-05 | CureVac AG | Novel lassa virus rna molecules and compositions for vaccination |
CN113015741A (en) | 2018-09-18 | 2021-06-22 | 桑格摩生物治疗股份有限公司 | Programmed cell death 1(PD1) specific nucleases |
SG11202106666UA (en) | 2018-12-21 | 2021-07-29 | Curevac Ag | Methods for rna analysis |
WO2020128031A2 (en) | 2018-12-21 | 2020-06-25 | Curevac Ag | Rna for malaria vaccines |
SG11202106987WA (en) | 2019-01-11 | 2021-07-29 | Acuitas Therapeutics Inc | Lipids for lipid nanoparticle delivery of active agents |
JP2022518399A (en) | 2019-01-14 | 2022-03-15 | ジェネンテック, インコーポレイテッド | How to Treat Cancer with PD-1 Axial Binding Antagonists and RNA Vaccines |
US20220133908A1 (en) | 2019-02-08 | 2022-05-05 | Curevac Ag | Coding rna administered into the suprachoroidal space in the treatment of ophthalmic diseases |
TW202104249A (en) | 2019-04-23 | 2021-02-01 | 美商聖加莫治療股份有限公司 | Modulators of chromosome 9 open reading frame 72 gene expression and uses thereof |
EP3986452A1 (en) | 2019-06-18 | 2022-04-27 | CureVac AG | Rotavirus mrna vaccine |
CA3144902A1 (en) | 2019-08-14 | 2022-01-19 | Andreas Thess | Rna combinations and compositions with decreased immunostimulatory properties |
BR112022011803A2 (en) | 2019-12-20 | 2022-08-30 | Curevac Ag | LIPID NANOPARTICLES FOR NUCLEIC ACIDS DELIVERY |
JP2023512654A (en) | 2020-01-31 | 2023-03-28 | ジェネンテック, インコーポレイテッド | Methods for Inducing Neoepitope-Specific T Cells Using PD-1 Axis Binding Antagonists and RNA Vaccines |
US11576966B2 (en) | 2020-02-04 | 2023-02-14 | CureVac SE | Coronavirus vaccine |
DE202021004130U1 (en) | 2020-02-04 | 2022-10-26 | Curevac Ag | Coronavirus Vaccine |
EP3901261A1 (en) | 2020-04-22 | 2021-10-27 | BioNTech RNA Pharmaceuticals GmbH | Coronavirus vaccine |
MX2022015132A (en) | 2020-05-29 | 2023-03-08 | CureVac SE | Nucleic acid based combination vaccines. |
CA3181193A1 (en) | 2020-06-04 | 2021-12-09 | Mario Perkovic | Rna replicon for versatile and efficient gene expression |
EP4172194A1 (en) | 2020-07-31 | 2023-05-03 | CureVac SE | Nucleic acid encoded antibody mixtures |
CN113234775A (en) * | 2020-08-20 | 2021-08-10 | 深圳市瑞吉生物科技有限公司 | Cap analog with Cap2 structure 5' structure, and preparation method and application thereof |
US20220064596A1 (en) | 2020-08-25 | 2022-03-03 | Kite Pharma, Inc. | T cells with improved functionality |
CA3170743A1 (en) | 2020-08-31 | 2022-03-03 | Susanne RAUCH | Multivalent nucleic acid based coronavirus vaccines |
AU2021341829A1 (en) | 2020-09-08 | 2023-04-06 | BioNTech SE | Systems and methods for producing pharmaceutical compositions using peristaltic pumps and dampeners |
CA3201552A1 (en) | 2020-12-09 | 2022-06-16 | Thomas ZIEGENHALS | Rna manufacturing |
WO2022137133A1 (en) | 2020-12-22 | 2022-06-30 | Curevac Ag | Rna vaccine against sars-cov-2 variants |
BR112023012303A2 (en) | 2020-12-22 | 2024-02-15 | CureVac SE | RNA VACCINE AGAINST SARS-COV-2 VARIANTS |
WO2022135993A2 (en) | 2020-12-22 | 2022-06-30 | Curevac Ag | Pharmaceutical composition comprising lipid-based carriers encapsulating rna for multidose administration |
US20240102065A1 (en) | 2021-01-27 | 2024-03-28 | CureVac SE | Method of reducing the immunostimulatory properties of in vitro transcribed rna |
EP4313152A1 (en) | 2021-03-26 | 2024-02-07 | GlaxoSmithKline Biologicals S.A. | Immunogenic compositions |
CA3171429A1 (en) | 2021-03-31 | 2022-09-30 | Alexander SCHWENGER | Syringes containing pharmaceutical compositions comprising rna |
WO2022233880A1 (en) | 2021-05-03 | 2022-11-10 | Curevac Ag | Improved nucleic acid sequence for cell type specific expression |
WO2022235853A1 (en) | 2021-05-04 | 2022-11-10 | BioNTech SE | Immunogen selection |
AU2022317263A1 (en) | 2021-07-29 | 2024-01-04 | BioNTech SE | Compositions and methods for treatment of melanoma |
CA3171750A1 (en) | 2021-07-30 | 2023-02-02 | Tim SONNTAG | Mrnas for treatment or prophylaxis of liver diseases |
IL309505A (en) | 2021-09-03 | 2024-02-01 | CureVac SE | Novel lipid nanoparticles for delivery of nucleic acids |
CA3230056A1 (en) | 2021-09-03 | 2023-03-09 | Patrick Baumhof | Novel lipid nanoparticles for delivery of nucleic acids comprising phosphatidylserine |
CN113957108A (en) * | 2021-09-09 | 2022-01-21 | 上海兆维科技发展有限公司 | Synthesis method of capped RNA and capped RNA transcription reaction solution |
AU2022369342A1 (en) | 2021-10-18 | 2024-03-14 | BioNTech SE | Modified replicable rna and related compositions and their use |
WO2023066874A1 (en) | 2021-10-18 | 2023-04-27 | BioNTech SE | Methods for determining mutations for increasing modified replicable rna function and related compositions and their use |
WO2023138786A1 (en) | 2022-01-21 | 2023-07-27 | BioNTech SE | Analysis of rna molecules using catalytic nucleic acids |
WO2023144330A1 (en) | 2022-01-28 | 2023-08-03 | CureVac SE | Nucleic acid encoded transcription factor inhibitors |
WO2023166425A1 (en) | 2022-03-01 | 2023-09-07 | Crispr Therapeutics Ag | Methods and compositions for treating angiopoietin-like 3 (angptl3) related conditions |
US20230293646A1 (en) | 2022-03-21 | 2023-09-21 | Crispr Therapeutics Ag | Methods and compositions for treating lipoprotein-related diseases |
WO2023213378A1 (en) | 2022-05-02 | 2023-11-09 | BioNTech SE | Replicon compositions and methods of using same for the treatment of diseases |
WO2023227608A1 (en) | 2022-05-25 | 2023-11-30 | Glaxosmithkline Biologicals Sa | Nucleic acid based vaccine encoding an escherichia coli fimh antigenic polypeptide |
WO2023237726A1 (en) | 2022-06-10 | 2023-12-14 | Pantarhei Oncology B.V. | An intracellular tumor-specific variant of human zona pellucida glycoprotein 3 and nucleic acids coding therefor for use in the treatment of cancer |
WO2024002985A1 (en) | 2022-06-26 | 2024-01-04 | BioNTech SE | Coronavirus vaccine |
CN114941018B (en) * | 2022-06-28 | 2023-09-22 | 翌圣生物科技(上海)股份有限公司 | Synthesis method of cap1 cap analogue |
WO2024017479A1 (en) | 2022-07-21 | 2024-01-25 | BioNTech SE | Multifunctional cells transiently expressing an immune receptor and one or more cytokines, their use and methods for their production |
WO2024056856A1 (en) | 2022-09-15 | 2024-03-21 | BioNTech SE | Systems and compositions comprising trans-amplifying rna vectors with mirna |
WO2024068545A1 (en) | 2022-09-26 | 2024-04-04 | Glaxosmithkline Biologicals Sa | Influenza virus vaccines |
Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20050227331A1 (en) * | 1999-10-15 | 2005-10-13 | Yale University | Conjoined polynucleotide catalysts |
US20060252115A1 (en) * | 2002-03-25 | 2006-11-09 | Edward Darzynkiewicz | Synthesis and use of anti-reverse mRNA cap analogues |
Family Cites Families (34)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4854610A (en) * | 1988-02-10 | 1989-08-08 | Bertek, Inc. | Method of making laminated articles and articles made therefrom |
US5470967A (en) * | 1990-04-10 | 1995-11-28 | The Dupont Merck Pharmaceutical Company | Oligonucleotide analogs with sulfamate linkages |
US5643780A (en) * | 1992-04-03 | 1997-07-01 | Isis Pharmaceuticals, Inc. | Compositions and methods for modulating RNA activity through modification of the 5' cap structure of RNA |
US5653472A (en) * | 1995-07-25 | 1997-08-05 | The Standard Register Company | Form having detachable wristband and labels |
WO1998047912A1 (en) * | 1997-04-22 | 1998-10-29 | Life Technologies, Inc. | Methods for the production of aslv reverse transcriptases composed of multiple subunits |
US7017294B2 (en) * | 2002-09-27 | 2006-03-28 | Laser Band, Llc | Wristband/cinch with inboard label assembly business form and method |
US7386949B2 (en) * | 1997-10-14 | 2008-06-17 | Laser Band, Llc | Special precautions self-laminating wristband business form and method |
US6510634B1 (en) * | 1997-10-14 | 2003-01-28 | Laser Band, Llc | Multiple computer generated multi-web moisture proof identification bracelets on a single form with window |
US7017293B2 (en) * | 2002-09-27 | 2006-03-28 | Laser Band, Llc | Wristband/cinch with label assembly business form and method |
US7047682B2 (en) * | 2002-09-27 | 2006-05-23 | Laser Band, Llc | Wristband/label assembly business form and method |
US6000160A (en) * | 1997-10-14 | 1999-12-14 | Riley; James M. | Computer generated moisture proof identification bracelet |
US6016618A (en) * | 1997-11-17 | 2000-01-25 | Avery Dennison Corporation | Laminated article |
US20040261644A1 (en) * | 2001-09-14 | 2004-12-30 | Stewart Thomas R. | Medical patient labeling system and method |
US6788687B2 (en) * | 2001-10-30 | 2004-09-07 | Qualcomm Incorporated | Method and apparatus for scheduling packet data transmissions in a wireless communication system |
US6836215B1 (en) * | 2002-01-22 | 2004-12-28 | The Standard Register Company | Printable identification band with top strip for RFID chip attachment |
US7316358B2 (en) * | 2002-03-18 | 2008-01-08 | Precision Dynamics Corporation | Identification band with adhesively attached coupling elements |
US6971200B2 (en) * | 2002-09-13 | 2005-12-06 | Chicago Tag & Label | Form having a removable wristband and labels |
US7000951B2 (en) * | 2002-09-13 | 2006-02-21 | Chicago Tag And Label, Inc. | Form having a removable wristband and labels |
US7520077B2 (en) * | 2004-06-17 | 2009-04-21 | Laser Band, Llc | Cushioned wristband with self-laminating identity tag |
US20050181165A1 (en) * | 2002-11-13 | 2005-08-18 | Franko Joseph D.Sr. | Glue-applied resealable expanded content label |
US7322613B2 (en) * | 2002-12-17 | 2008-01-29 | Precision Dynamic, Corporation | Multi-part form having detachable wristband, labels and cards or the like |
US7222748B2 (en) * | 2003-09-26 | 2007-05-29 | Royal Vendors, Inc. | Clear door vending machine |
US20050091896A1 (en) * | 2003-10-30 | 2005-05-05 | Kotik Mark M. | Identification band with detachable machine-readable lables |
US7320194B2 (en) * | 2004-06-01 | 2008-01-22 | Precision Dynamics Corporation | Adhesive wristband without removable release liner |
US7658026B2 (en) * | 2006-10-27 | 2010-02-09 | Laser Band, Llc | Wristband with snap closure and patent id label |
US20050285385A1 (en) * | 2004-06-28 | 2005-12-29 | Bova Antonio V | Emergency medical analysis form with detachable patient identification piece and method of using same |
US7417541B2 (en) * | 2004-10-08 | 2008-08-26 | Bartronics America, Inc. | Identification band with regions having electro-magnetically detectable regions |
US20060113788A1 (en) * | 2004-11-30 | 2006-06-01 | Laser Band, Llc. | Laser printable business form having a self laminating wristband and a self laminating strip label |
US7810267B2 (en) * | 2005-04-21 | 2010-10-12 | Avery Dennison Corporation | Patient identification products |
US20070120358A1 (en) * | 2005-11-30 | 2007-05-31 | Waggoner Bryce C | Patient wristband form |
US20070283607A1 (en) * | 2006-06-13 | 2007-12-13 | Printmark Industries, Inc. | Printed identification band and method of manufacturing same |
US20080067802A1 (en) * | 2006-08-24 | 2008-03-20 | Tri-State Hospital Supply Corporation | Self-laminating label for a wristband |
US8424115B2 (en) * | 2006-10-27 | 2013-04-23 | Laser Band, Llc | Wristband with contoured comfort sides |
EP2152160B1 (en) * | 2007-06-14 | 2013-05-01 | Precision Dynamics Corporation | A closure mechanism for an identification medium adapted for receiving indicia forming material and dual closure means |
-
2008
- 2008-06-19 AU AU2008265683A patent/AU2008265683B2/en active Active
- 2008-06-19 CA CA2692906A patent/CA2692906C/en active Active
- 2008-06-19 ES ES08771474.7T patent/ES2500515T3/en active Active
- 2008-06-19 US US12/280,282 patent/US8153773B2/en active Active - Reinstated
- 2008-06-19 CN CN201410246751.1A patent/CN104072561B/en active Active
- 2008-06-19 WO PCT/US2008/067494 patent/WO2008157688A2/en active Application Filing
- 2008-06-19 DK DK08771474.7T patent/DK2167523T3/en active
- 2008-06-19 PT PT87714747T patent/PT2167523E/en unknown
- 2008-06-19 EP EP08771474.7A patent/EP2167523B1/en active Active
- 2008-06-19 PL PL08771474T patent/PL2167523T3/en unknown
- 2008-06-19 CN CN201710815709.0A patent/CN107501370B/en active Active
- 2008-06-19 SI SI200831256T patent/SI2167523T1/en unknown
- 2008-06-19 EA EA201070030A patent/EA017740B1/en not_active IP Right Cessation
- 2008-06-19 CN CN200880102959.9A patent/CN101855231B/en active Active
-
2014
- 2014-08-18 HR HRP20140771AT patent/HRP20140771T1/en unknown
- 2014-09-08 CY CY20141100718T patent/CY1115525T1/en unknown
-
2015
- 2015-01-27 HK HK15100888.8A patent/HK1200461A1/en unknown
Patent Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20050227331A1 (en) * | 1999-10-15 | 2005-10-13 | Yale University | Conjoined polynucleotide catalysts |
US20060252115A1 (en) * | 2002-03-25 | 2006-11-09 | Edward Darzynkiewicz | Synthesis and use of anti-reverse mRNA cap analogues |
Non-Patent Citations (4)
Title |
---|
GRUDZIEN-NOGALSKA, EWA ET AL.: "Phosphorothioate cap analogs stabilize mRNA and increase translational efficiency in mammalian cells", RNA, vol. 13, no. 10, 2007, pages 1745 - 1755, XP002554207 * |
JEMIELITY, JACEK ET AL.: "Novel anti-reverse cap analogs with superior translational properties", RNA, vol. 9, no. 9, 2003, pages 1108 - 1122, XP002466761 * |
KOWALSKA, JOANNA ET AL.: "Synthesis and characterization of mRNA cap analogs containing phosphorothioate substitutions that bind tightly to eLF4E and are resistant to the decapping pyrophosphatase DcpS", RNA, vol. 14, no. 6, 2008, pages 1119 - 1131, XP002554206 * |
WIECZOREK, ZBIGNIEW ET AL.: "Fluorescence and NMR studies of intramolecular stacking of mRNA cap-analogues", BIOCHIMCA ET BIOPHYICA ACTA, vol. 1354, 1997, pages 145 - 152, XP008127342 * |
Cited By (13)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US8822663B2 (en) | 2010-08-06 | 2014-09-02 | Moderna Therapeutics, Inc. | Engineered nucleic acids and methods of use thereof |
US9186372B2 (en) | 2011-12-16 | 2015-11-17 | Moderna Therapeutics, Inc. | Split dose administration |
US9295689B2 (en) | 2011-12-16 | 2016-03-29 | Moderna Therapeutics, Inc. | Formulation and delivery of PLGA microspheres |
US9220755B2 (en) | 2012-04-02 | 2015-12-29 | Moderna Therapeutics, Inc. | Modified polynucleotides for the production of proteins associated with blood and lymphatic disorders |
US9114113B2 (en) | 2012-04-02 | 2015-08-25 | Moderna Therapeutics, Inc. | Modified polynucleotides encoding citeD4 |
US9192651B2 (en) | 2012-04-02 | 2015-11-24 | Moderna Therapeutics, Inc. | Modified polynucleotides for the production of secreted proteins |
US9095552B2 (en) | 2012-04-02 | 2015-08-04 | Moderna Therapeutics, Inc. | Modified polynucleotides encoding copper metabolism (MURR1) domain containing 1 |
US8999380B2 (en) | 2012-04-02 | 2015-04-07 | Moderna Therapeutics, Inc. | Modified polynucleotides for the production of biologics and proteins associated with human disease |
US9301993B2 (en) | 2012-04-02 | 2016-04-05 | Moderna Therapeutics, Inc. | Modified polynucleotides encoding apoptosis inducing factor 1 |
US9303079B2 (en) | 2012-04-02 | 2016-04-05 | Moderna Therapeutics, Inc. | Modified polynucleotides for the production of cytoplasmic and cytoskeletal proteins |
US9572897B2 (en) | 2012-04-02 | 2017-02-21 | Modernatx, Inc. | Modified polynucleotides for the production of cytoplasmic and cytoskeletal proteins |
US9587003B2 (en) | 2012-04-02 | 2017-03-07 | Modernatx, Inc. | Modified polynucleotides for the production of oncology-related proteins and peptides |
US9675668B2 (en) | 2012-04-02 | 2017-06-13 | Moderna Therapeutics, Inc. | Modified polynucleotides encoding hepatitis A virus cellular receptor 2 |
Also Published As
Publication number | Publication date |
---|---|
CN101855231B (en) | 2014-06-11 |
EP2167523A4 (en) | 2011-06-15 |
AU2008265683A1 (en) | 2008-12-24 |
PL2167523T3 (en) | 2014-12-31 |
CN104072561A (en) | 2014-10-01 |
HRP20140771T1 (en) | 2014-11-07 |
WO2008157688A2 (en) | 2008-12-24 |
HK1200461A1 (en) | 2015-08-07 |
AU2008265683B2 (en) | 2013-08-29 |
ES2500515T3 (en) | 2014-09-30 |
EA017740B1 (en) | 2013-02-28 |
CN104072561B (en) | 2017-12-22 |
EP2167523B1 (en) | 2014-07-23 |
US8153773B2 (en) | 2012-04-10 |
CN107501370B (en) | 2021-06-18 |
EA201070030A1 (en) | 2010-06-30 |
DK2167523T3 (en) | 2014-09-08 |
CN101855231A (en) | 2010-10-06 |
PT2167523E (en) | 2014-09-22 |
CN107501370A (en) | 2017-12-22 |
CA2692906A1 (en) | 2008-12-24 |
US20100233757A1 (en) | 2010-09-16 |
EP2167523A2 (en) | 2010-03-31 |
CA2692906C (en) | 2016-01-19 |
CY1115525T1 (en) | 2017-01-04 |
SI2167523T1 (en) | 2014-09-30 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
WO2008157688A3 (en) | Synthesis and use of anti-reverse phosphorothioate analogs of the messenger rna cap | |
WO2009149253A3 (en) | Mrna cap analogs | |
CN104254607B (en) | MicroRNA compounds and methods for modulating MIR-21 activity | |
AU2018224380A1 (en) | Compositions and methods for treatment of proprotein convertase subtilisin/kexin type 9 (PCSK9)-related disorders | |
EP3222726A1 (en) | Further novel forms of interfering rna molecules | |
JP2012506254A5 (en) | ||
WO2008116860A3 (en) | Dsrna compositions and methods for treating hpv infections | |
WO2006078414A3 (en) | METHODS AND COMPOSITIONS CONCERNING siRNA'S AS MEDIATORS OF RNA INTERFERENCE | |
WO2007134161A3 (en) | Compositions and methods for inhibiting expression of the pcsk9 gene | |
WO2007051045A3 (en) | Compositions and methods for inhibiting expression of huntingtin gene | |
WO2007056326A3 (en) | Compositions and methods for inhibiting expression of nav1.8 gene | |
EP2261333A3 (en) | Pharmaceutical composition comprising anti-miRNA antisense oligonucleotides | |
EP2261334A3 (en) | Modified polynucleotides for use in RNA interference | |
WO2007087436A3 (en) | Modification of chemical forces of bone constructs | |
WO2007115168A3 (en) | Compositions and methods for inhibiting expression of eg5 gene | |
WO2007112753A3 (en) | Pharmaceutical composition comprising anti-mirna antisense oligonucleotides | |
WO2006032041A3 (en) | Compositions and methods for inhibiting expression of anti-apoptotic genes | |
WO2008036933A3 (en) | Compositions and methods for inhibiting expression of the hamp gene | |
WO2008036638A3 (en) | Rnai modulation of scap and therapeutic uses thereof | |
WO2011046983A3 (en) | Methods and compositions for modulating gene expression using oligonucleotide based drugs administered in vivo or in vitro | |
WO2007147067A8 (en) | Methods and compositions for regulating cell cycle progression | |
WO2007127919A3 (en) | Compositions and methods for inhibiting expression of a gene from the jc virus | |
AU2002331356A1 (en) | Nanoparticles for dna administration to a target organ | |
WO2018115602A1 (en) | Therapeutic peptides | |
WO2007137220A3 (en) | Compositions and methods for inhibiting expression of ikk-b gene |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
WWE | Wipo information: entry into national phase |
Ref document number: 200880102959.9 Country of ref document: CN |
|
WWE | Wipo information: entry into national phase |
Ref document number: 12280282 Country of ref document: US |
|
121 | Ep: the epo has been informed by wipo that ep was designated in this application |
Ref document number: 08771474 Country of ref document: EP Kind code of ref document: A2 |
|
NENP | Non-entry into the national phase |
Ref country code: DE |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2008771474 Country of ref document: EP |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2692906 Country of ref document: CA |
|
WWE | Wipo information: entry into national phase |
Ref document number: 100/KOLNP/2010 Country of ref document: IN |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2008265683 Country of ref document: AU Ref document number: 201070030 Country of ref document: EA |
|
ENP | Entry into the national phase |
Ref document number: 2008265683 Country of ref document: AU Date of ref document: 20080619 Kind code of ref document: A |